August 12, 2019 / 2:34 PM / 7 days ago

Congo trial of Ebola treatments switches to focus on two drugs

LONDON, Aug 12 (Reuters) - A clinical trial of four potential Ebola treatments in Congo has been narrowed to focus on two of the experimental drugs - Regeneron’s REGN-EB3 and a monoclonal antibody called mAb114 - after they showed encouraging results, scientists leading the trial said on Monday.

Two other experimental treatments - ZMapp, an intravenous treatment made by Mapp Biopharmaceutical and Remdesivir, made by Gilead Sciences, will now be dropped from the trial, the researchers said. (Reporting by Kate Kelland, editing by Deepa Babington)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below